Allergan Plc (AGN)
$198.32 0.94 (0.47%)
19:03 EST AGN Stock Quote Delayed 15 Minutes
Previous Close $198.32
Market Cap 77.83B
PE Ratio -38.66
Volume (Avg. Vol.) 3.06M
Day's Range 197.94 - 199.40
52-Week Range 114.27 - 202.21
Dividend & Yield 2.88 (1.45%)
AGN Stock Predictions, Articles, and Allergan Plc News
- From InvestorPlace
- From the Web
Not all stocks are lifted by a rising tide, especially these blue-chip stocks that look like they're in for some trouble.
AMZN, TAP, ALGN and AGN are just some of the stocks on the rise as we head into the second quarter of the year.
As Goldman Sachs moves away from the strong balance sheet investing strategy, here are 6 new stocks to buy.
Biotech stocks offer more than just capital gains; some of them pay dividends. Here are three dividend-paying biotechs to consider.
Don't ignore Dow Jones stocks. They can still power your portfolio. Here are 5 of the best to own in 2019 and beyond!
Pharmaceutical stocks have been on the rebound and many are raising their prices this year. What does that mean for business?
AGN stock is taking a beating today on some bad news about Allergan's breast implants and concerns over links to cancer.
Biotech stocks can still pay you some big yields. Here are five of the best dividend stocks in the pharma sector.
Biogen stock reaffirmed its dominance in MS and the neurosciences market. At a low P/E mutliple, investors should look at BIIB again.
Drug stocks have been beaten up ever since the 2015 collapse of Valeant, but many of them are now too cheap to ignore.
The short-term outlook on AGN stock is messy due to drug pricing issues. But the long-term outlook remains promising - thanks to the company's wide moat and stable growth prospects.
Pfizer renewed the drug price hike cycle after it raised them for around 40 products. If other biotech stocks follow, profits will soar.
Teva Pharmaceuticals is quietly moving higher on the stock market for good reason: worries over pricing and the impact of competition in generics is getting clearer. Teva stock is a great long-term bet.
Axovant Sciences soared last week after AXON stock presented AXO-Lenti-PD, a gene therapy product that treats Parkinson's Disease.
Allergan (AGN) raised its quarterly and yearly outlook but the stock slumped in trading after the earnings announcement. A big write-down is hammering the stock price.
From Talk Markets
From Talk Markets
Navellier RatingsPowered by Portfolio Grader